Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated…

By J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem and 10 more. Journal of Clinical Oncology, 2010

1,809 citations recorded by the source corpus.

Subfields: Biotechnology, Oncology

View Paper: https://www.semanticscholar.org/paper/0be3933c5ff91e9bee4a006a6325bf8340e8e3f8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Fortunato Ciardiello

Citations in the corpus

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, neutral): “• FOLFOX note 1 [57, 58] +Bmab [54] • CapeOX note 2 + Bmab [59, 60] • FOLFIRI note 3 [61, 62] +Bmab [63, 64] • FOLFOX + Cmab/Pmab [65, 66] • FOLFIRI + Cmab/Pmab [67, 68] • FOLFOXIRI note 4 [69] • Infusional 5-FU + l-LV [70, 71] +Bmab [72, 73] • Cape [74, 75] + Bmab [76] • UFT + LV [77–79]”
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011, background): “S2, and Supplementary Table S2), again in agreement with clinical evidence (7-12).”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “The monoclonal antibodies bevacizumab (anti-VEGF) and cetuximab and panitumumab (anti-EGFR) have been shown to improve the clinical outcome of patients with mCRC when combined with combination chemotherapy regimens in the first-line setting [I, B] [43-46, 48-50, 101, 244, 245].”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Panitumumab also increases objective RR (ORR), PFS and OS when combined with FOLFOX in the first-line treatment of RAS WT mCRC [24, 25].”
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. (2013, neutral): “Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015, background): “was apparent when panitumumab was combined with FOLFOX4 in patients with KRAS exon 2 mutations.(5) Activating missense mutations of KRAS at codons other than 12 or 13 have been identified in a wide range of tumor types, including CRC.”
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, methodology): “Methods The present pooled analyses are based on data from the randomized CRYSTAL (NCT00154102) [33], PRIME (NCT00364013) [34], PEAK (NCT00819780) [35], FIRE-3 (NCT00433927) [36, 37], 1714 | Arnold et al. Volume 28 | Issue 8 | 2017 Downloaded from https://academic.oup.com/annonc/article-abstract/28/”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “7 Systemic therapy algorithm for unresectable colorectal cancer 1 3 FOLFIRI + AFL (see comment ⑥) [194] S‑1 + IRI [195] + BEV IRI [196] + BEV [197] FOLFIRI (or IRI) + CET, FOLFIRI + PANI [198, 199] IRI + CET [200] or IRI + PANI [201] Pembro (see comment ⑩) [202] (b) For patients who are refractory o”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “98) 3 [60, 61]”